DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Provenge (Sipuleucel-T) - Summary

 
 



PROVENGE SUMMARY

PROVENGE consists of autologous peripheral blood mononuclear cells, including antigen presenting cells (APCs), that have been activated during a defined culture period with a recombinant human protein, PAP-GM-CSF, consisting of prostatic acid phosphatase (PAP), an antigen expressed in prostate cancer tissue, linked to granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune cell activator. The patient's peripheral blood mononuclear cells are obtained via a standard leukapheresis procedure approximately 3 days prior to the infusion date. Due to the autologous nature of PROVENGE, it is important that the patient and physician adhere to the personalized leukapheresis and infusion schedules. The active components of PROVENGE are autologous APCs and PAP-GM-CSF. During culture, the recombinant antigen can bind to and be processed by APCs into smaller protein fragments. The recombinant antigen is designed to target APCs, and may help direct the immune response to PAP. Minimal residual levels of the intact PAP-GM-CSF are detectable in the final PROVENGE product.

PROVENGE (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
See all Provenge indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Provenge (Sipuleucel-T)

Screening Men With a Family History of Prostate Cancer
Source: Medscape Hematology-Oncology Headlines [2014.12.18]
Men with a family history of prostate cancer may be more likely to have prostate cancer themselves, but do they benefit from the screening process? Dr Gerald Chodak discusses the latest research.
Medscape Urology

A yardstick to measure the malignancy of prostate cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2014.12.10]
A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer.

Prevention of prostate cancer growth and spread achieved in animal studies
Source: Lung Cancer News From Medical News Today [2014.12.09]
Researchers at Georgetown Lombardi Comprehensive Cancer Center have completed a critical step in the journey from a basic science discovery in the lab to a potential clinical application, showing...

Xtandi™ (enzalutamide) now licensed for use in the UK to treat men with advanced prostate cancer, following initial hormone treatment failure
Source: Prostate / Prostate Cancer News From Medical News Today [2014.12.08]
XTANDI TM(enzalutamide) is now licensed in Europe and is already funded in England on the Cancer Drugs Fund,2 for the treatment of adult men with metastatic castration-resistant prostate cancer...

Association between common prostate cancer treatment and decreased survival in older men
Source: Prostate / Prostate Cancer News From Medical News Today [2014.12.08]
A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital.

more news >>

Published Studies Related to Provenge (Sipuleucel-T)

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. [2013]
phosphatase/granulocyte-macrophage colony-stimulating factor antigen... CONCLUSIONS: There is potential to build on sipuleucel-T to further advance

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. [2013]
responses to overall survival (OS)... CONCLUSION: Sipuleucel-T broadly engages the immune system by activating APCs ex

Cancer immunotherapy: sipuleucel-T and beyond. [2011.08]
In April 2010, sipuleucel-T became the first anticancer vaccine approved by the United States Food and Drug Administration. Different from the traditional chemotherapy agents that produce widespread cytotoxicity to kill tumor cells, anticancer vaccines and immunotherapies focus on empowering the immune system to overcome the tumor.

Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. [2011.07.01]
CONCLUSIONS: No significant difference in time to BF could be shown. The finding of increased PSADT in the sipuleucel-T arm is consistent with its biologic activity in ADPC. Long-term follow-up will be necessary to determine if clinically important events, such as distant failure, are affected by therapy. Treatment was generally well tolerated.

Sipuleucel-T: in metastatic castration-resistant prostate cancer. [2011.01.01]
Sipuleucel-T is an autologous active cellular immunotherapy used in the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC)... infusion-related events, such as chills and fever) generally occurred within the first day after administration of sipuleucel-T and resolved within 2 days.

more studies >>

Clinical Trials Related to Provenge (Sipuleucel-T)

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer [Recruiting]
The main purpose of this study is to determine whether ADT started before or after sipuleucel-T leads to a better immune system response. This study will also evaluate the safety of sipuleucel-T treatment, immune system responses over time, the characteristics of sipuleucel-T, and changes in prostate specific antigen (PSA) values over time.

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402) [Recruiting]
This study is being conducted to examine the immune response generated by sipuleucel-T in subjects previously treated with sipuleucel-T in the androgen dependent setting. The study will also assess the safety of receiving up to 3 additional infusions of sipuleucel-T. This is an open-label, uncontrolled, multicenter study, conducted in up to 14 clinical trial sites. The anticipated duration of the study is approximately 6 years.

Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) [Recruiting]
The purpose of this study is to evaluate the impact of concurrent versus sequential administration of abiraterone acetate plus prednisone on product parameters of sipuleucel-T, and to assess the safety and efficacy of sipuleucel-T with concurrent or sequential administration of abiraterone acetate plus prednisone in men with metastatic castrate resistant prostate cancer.

Sipuleucel-T Manufacturing Demonstration Study [Recruiting]
To demonstrate that sipuleucel-T can be successfully manufactured for subjects with metastatic castrate resistant prostate cancer (mCRPC) at a European manufacturing facility.

Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer [Recruiting]
This is an open label, Phase 2 trial of immunotherapy with sipuleucel-T as neoadjuvant treatment in men with localized prostate cancer.

more trials >>

Reports of Suspected Provenge (Sipuleucel-T) Side Effects

Asthenia (40)Chills (37)Fall (33)Anaemia (32)Disease Progression (31)Fatigue (31)Malaise (30)Hypotension (28)Nausea (26)Dehydration (26)more >>


Page last updated: 2014-12-18

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014